Capecitabine and Docetaxel in Advanced/Recurrent Cervical Cancer
Status:
Completed
Trial end date:
2007-07-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the effectiveness and side effects of the drugs
capecitabine and docetaxel in the treatment of cervical cancer. Capecitabine is approved by
the FDA for the treatment of breast and colon cancer. Docetaxel is approved in the treatment
of breast and lung cancer. The use of capecitabine and docetaxel in this study for the
treatment of cervical cancer is considered investigational. Eligible subjects will take the
drug capecitabine (Xeloda) by mouth twice a day every 12 hours, for fourteen consecutive days
followed by a 7 day rest period. Subjects will also receive the drug docetaxel (Taxotere)
intravenously (in the vein) every three weeks.